NCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
Clinical Trials
33 trialsNCT03853109 2025-07-20
AMG 404 in Patients With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT04882917 2025-03-07
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
EMD Serono
Phase 1 Completed
NCT04074759 2025-01-23
FPT155-001
Five Prime Therapeutics, Inc.
Phase 1 Terminated
NCT03854227 2025-01-13
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT04727554 2025-01-06
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT03666143 2024-11-04
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT02516813 2024-10-15
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
EMD Serono
Phase 1 Completed
NCT02994953 2024-09-20
COMBO
EMD Serono
Phase 1 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT02261285 2024-05-06
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT03954704 2023-11-21
Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT01773421 2023-06-22
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT02197572 2023-01-23
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT04049617 2022-10-06
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT02734433 2022-04-25
Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT03348514 2021-12-03
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
Phase 1 Completed
NCT03497429 2021-11-09
A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT03991494 2021-09-27
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
BeiGene
Phase 1 Completed
NCT03077607 2021-06-30
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02997163 2021-01-05
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Pfizer
Phase 1 Completed
NCT00747474 2019-11-18
Phase I Study of Intravenous LipotecanĀ® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
Taiwan Liposome Company
Phase 1 Completed
NCT00962091 2019-03-12
Study of MLN8237 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT01094288 2019-02-15
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Takeda
Phase 1 Completed
NCT02122770 2019-01-07
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT03070548 2018-12-17
A Study of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT00635778 2018-10-09
MK-0646-002
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00632424 2016-03-10
Phase 1 Trial of Oral Ixabepilone
R-Pharm
Phase 1 Terminated
NCT01004822 2015-11-20
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00932126 2015-10-28
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00557856 2015-10-19
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01469052 2012-03-26
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00908908 2012-03-09
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed